April 24, 2020 / 12:25 PM / a month ago

BRIEF-Tonix Pharmaceuticals Achieves 50 Percent Enrollment In Phase 3 Relief Study Of Tnx-102 Sl

April 24 (Reuters) - Tonix Pharmaceuticals Holding Corp :

* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 RELIEF STUDY OF TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR MANAGEMENT OF FIBROMYALGIA

* TONIX PHARMACEUTICALS HOLDING CORP - TOPLINE RESULTS OF APPROXIMATELY 470 PARTICIPANTS WITH FIBROMYALGIA EXPECTED IN Q1 OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below